Prescription medicine
Paromomycin Brand names: Humatin
Paromomycin (Humatin) is a prescription medicine. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
Check it at the source: the paromomycin FDA label on DailyMed (effective November 13, 2025, Waylis Therapeutics LLC); every paromomycin label on DailyMed.
Highlights of the record
FDA label of November 13, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageParomomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis);
Forms and strengths
- 250 mg
Capsule.
On the market
- Generic approvals
- 4 first March 24, 1969; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 1 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 102 through July 30, 2026
What is paromomycin used for?
From the label: indications and usageParomomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. […]
FDA pharmacologic class: Antiprotozoal.
Source: FDA drug label (Humatin), ANDA065173 (Heritage), as published by Waylis Therapeutics LLC, effective November 13, 2025 (SPL set a725f022-ec3c-430d-8021-96c861b9893c), via openFDA; the full label on DailyMed
Is there a generic for paromomycin (Humatin)?
The FDA approved the first generic paromomycin on March 24, 1969. 4 generic applications are approved; 1 of them carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists paromomycin from 1 labeler under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the paromomycin label say about other medicines?
The paromomycin label names no other medicine on this site. The labels of 4 other medicines name paromomycin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Other labels that name paromomycin
Source: FDA drug label (Humatin), ANDA065173 (Heritage), as published by Waylis Therapeutics LLC, effective November 13, 2025 (SPL set a725f022-ec3c-430d-8021-96c861b9893c), via openFDA; the full label on DailyMed
What do FAERS reports show for paromomycin?
The FDA Adverse Event Reporting System holds 102 reports that list paromomycin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 15 are coded as a death and 34 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other antiprotozoals
- the pharmacologic class, with prices and generics
- Paromomycin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other